Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
$3.30
-$0.08(-4.37%)
At close: 4:00 PM EST
$3.30
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$0.86 - $3.32
Previous CloseN/A
Volume101.31K
Average Volume (3M)415.59K
Market Cap
$199.89M
Enterprise Value$183.90M
Total Cash (Recent Filing)$126.61M
Total Debt (Recent Filing)$30.84M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Mar 30, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding60,573,425
10 Day Avg. Volume506,634
30 Day Avg. Volume415,590
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.57
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.18K
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$6.75Price Target Upside104.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS Penetration And TolerabilityEnhanced brain transfer of the TfR-equipped fusion proteins could permit lower systemic doses, reducing anemia risk and improving tolerability.
Mechanism And EfficacyAntibody design that selectively targets toxic oligomers while avoiding abundant plaque may improve clinical effectiveness and reduce off-target effects compared with competitors.
Regulatory ProgressRegulatory acceptance of a subcutaneous induction filing could broaden patient access by enabling more convenient dosing and stimulate wider adoption of anti-amyloid therapies.
Bears Say
Efficacy UncertaintyReliance on plaque reduction as the regulatory endpoint rather than direct cognitive benefit raises the risk that meaningful clinical improvement may be delayed if high initial exposure is required to saturate plaque.
Safety ProfileThe subcutaneous formulation appears not to reduce the primary brain swelling risk relative to intravenous dosing, limiting any improvement to the therapy's risk–benefit balance.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $0.85 and its highest was $3.31 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $199.89M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Mar 30, 2026 which is in 26 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.603 by $0.163.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.45.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,573,425 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.603. Following the earnings report the stock price went down -1.015%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.75 (104.55% Upside)
$6.75 (104.55% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.87%
12-Months-Change
Fundamentals
Return on Equity
-85.93%
Trailing 12-Months
Asset Growth
-40.50%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS Company Deck
ABOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic partnerships, and financial management, with a focus on advancing Alzheimer's treatments. However, the operational loss was a noted concern.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$6.75
▲(104.55% Upside)
Technical Analysis
Ownership Overview
28.62% Insiders
7.79% Mutual Funds
13.02% Other Institutional Investors
48.00% Public Companies and Individual Investors